Alright, imagine you're on a school field trip to the stock market. Instead of teachers, we have something called "analysts". These analysts are like smart detectives who study companies very carefully and then give their opinions about whether they think a company's stocks will go up or down.

Today, some news came in that four of these analyst detectives changed their minds about some companies:

1. **Sage Therapeutics (SAGE)**: One analyst detective, Brian Abrahams from RBC Capital, said he isn't worried about this company anymore. He changed his mind from saying "be careful" to now saying "it's probably okay".

2. **EVERTEC (EVTC)**: Another analyst detective, James Faucette from Morgan Stanley, also changed his mind. He used to say "watch out", but now he thinks it's fine too.

3. **DT Midstream (DTM)**: An analyst from Citigroup named Spiro Dounis said this company went from "meh" to "buy me!".

4. **Palo Alto Networks (PANW) and Pebblebrook Hotel Trust (PEB)**: These two companies got upgrades too, which means more detectives now think their stocks are good ideas.

So, all these changes mean the analyst detectives have different opinions about these companies, and some of them changed their minds recently. Read from source...

In light of the recent changes in analyst ratings for several companies, let's analyze the provided information and address some potential criticisms or inconsistencies:

1. **Sage Therapeutics (SAGE):**
- *RBC Capital* upgraded SAGE from 'Underperform' to 'Sector Perform', maintaining the price target at $4.
- *Criticism:* The upgrade is a modest one, moving from underperformance within the sector to neutral performance, suggesting RBC's confidence in SAGE hasn't drastically improved. Moreover, the price target remains below the stock's closing price of $4.91 on Wednesday, indicating potential downside.

2. **EVERTEC (EVTC):**
- *Morgan Stanley* upgraded EVTC from 'Underweight' to 'Equal-Weight', raising the price target from $33 to $35.
- *Criticism:* While this upgrade is more substantial, as it moves out of 'Underweight', Morgan Stanley's new 'Equal-Weight' rating suggests they still see EVTC as a hold rather than an immediate buy. The price target adjustment seems modest given the stock's significant movement since the previous price target (EVTC closed at $34.84 on Wednesday).

3. **DT Midstream (DTM):**
- *Citigroup* upgraded DTM from 'Neutral' to 'Buy', raising the price target from $90 to $115.
- *Criticism:* Although this is a bullish upgrade, the new price target implies around 10% upside based on Wednesday's close of $102.73, which might not seem as attractive considering DTM's recent performance and analyst optimism.

4. **Palo Alto Networks (PANW):**
- *Rosenblatt* upgraded PANW from 'Neutral' to 'Buy', boosting the price target from $390 to $425.
- *Criticism:* With a new price target of $425, Rosenblatt sees around 8% upside in PANW based on Wednesday's closing price. While positive, this might not be as conviction-driven given PANW's recent outperformance.

5. **Pebblebrook Hotel Trust (PEB):**
- *Compass Point* upgraded PEB from 'Neutral' to 'Buy', maintaining the price target at $17.
- *Criticism:* Despite the upgrade, Compass Point's price target indicates they see substantial downside (around 39%) for PEB based on Wednesday's closing price of $12.37. This suggests their upgrade might be more about relative outperforming peers rather than an outright buy signal.

In summary, while these upgrades might seem promising at first glance, digging deeper uncovers potential criticisms and inconsistencies. As a critical reader or investor, it's essential to scrutinize analyst ratings and price targets carefully, considering both the bullish and bearish arguments, and make informed decisions based on one's investment objectives and risk tolerance.

**Positive**

The article reports several analyst upgrades for different stocks, indicating a positive sentiment overall:

1. Sage Therapeutics (SAGE) upgraded from "Underperform" to "Sector Perform"
2. EVERTEC (EVTC) upgraded from "Underweight" to "Equal-Weight"
3. DT Midstream (DTM) upgraded from "Neutral" to "Buy"
4. Palo Alto Networks (PANW) upgraded from "Neutral" to "Buy"
5. Pebblebrook Hotel Trust (PEB) upgraded from "Neutral" to "Buy"

These upgrades suggest that the analysts have a more favorable view of these companies' prospects, contributing to an overall positive sentiment in the article.

Based on the provided upgrades, here are comprehensive investment considerations for each stock, including potential risks:

1. **Sage Therapeutics (SAGE)**:
- *Upgrade*: RBC Capital from Underperform to Sector Perform
- *Price Target*: Maintained at $4
- *Recent Close*: $4.91
- *Potential Upside/Downside*: Around 3% upside if the price target is reached.
- *Investment Considerations*:
- Sage Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing novel medicines for neuroscience disorders.
- The upgrade may indicate increased confidence in the company's pipeline or financials, but no specific reason was provided.
- SAGE is quite volatile due to its pre-revenue status and reliance on clinical trial results. Consider this before investing.
- *Risks*:
- Clinical trial failures can significantly impact the stock price.
- The company has a history of burning cash rapidly, which could lead to funding issues if they don't achieve commercial success soon.

2. **EVERTEC (EVTC)**:
- *Upgrade*: Morgan Stanley from Underweight to Equal-Weight
- *Price Target*: Raised from $33 to $35
- *Recent Close*: $34.84
- *Potential Upside/Downside*: Around 1% upside if the price target is reached.
- *Investment Considerations*:
- EVERTEC provides merchant acquiring and payment processing services in Latin America.
- The upgrade suggests that Morgan Stanley believes EVTC's growth prospects are more inline with its peers, but not exceptionally strong (hence Equal-Weight).
- EVTC has been expanding its merchant ecosystem and diversifying its revenue streams.
- *Risks*:
- Economic slowdowns or currency fluctuations in Latin America could impact EVTC's business.
- Competition from established players like Visa and Mastercard, as well as fintech startups.

3. **DT Midstream (DTM)**:
- *Upgrade*: Citigroup from Neutral to Buy
- *Price Target*: Raised from $90 to $115
- *Recent Close*: $102.73
- *Potential Upside/Downside*: Around 12% upside if the price target is reached.
- *Investment Considerations*:
- DT Midstream operates pipelines and storage facilities in the Permian Basin and Delaware Basin.
- The upgrade indicates increased confidence in DTM's growth prospects, likely tied to the recovery in energy prices and production volumes.
- DTM offers a solid dividend yield (currently around 8%).
- *Risks*:
- A significant drop in energy prices could impact demand for DT Midstream's services.
- Regulatory risks and potential new pipeline projects could affect DTM's competitive position.

4. **Palo Alto Networks (PANW)**:
- *Upgrade*: Rosenblatt from Neutral to Buy
- *Price Target*: Boosted from $390 to $425
- *Recent Close*: $392.89
- *Potential Upside/Downside*: Around 8% upside if the price target is reached.
- *Investment Considerations*:
- Palo Alto Networks provides cybersecurity solutions to enterprises and governments worldwide.
- The upgrade suggests Rosenblatt believes PANW's growth will accelerate, possibly due to increasing global demand for enhanced cybersecurity measures.
- PANW is known for its strong product portfolio and services.
- *Risks*:
- Intense competition in the cybersecurity industry from large players like CrowdStrike, Fortinet, and Trend Micro.
- Geopolitical risks or economic downturns could slow down enterprise spending on PANW's solutions.

5. **Pebblebrook Hotel Trust (PEB)**:
- *Upgrade*: Compass Point from Neutral to Buy
- *Price Target*: Maintained at $17
- *Recent Close*: $12.37
- *Potential Upside/Downside*: Around 36% upside if the price target is reached.
- *Investment Considerations*:
- Pebblebrook Hotel Trust invests in upper-upscale, institutional-quality hotel properties located in urban markets.
- The upgrade indicates that Compass Point believes PEB's fundamentals will improve as travel demand rebounds post-pandemic.
- PEB offers an attractive dividend yield (currently around 8%).
- *Risks*:
- A slower recovery in travel demand due to geopolitical risks or new virus variants could impact PEB's performance.
- Competition from other hospitality REITs and changes in interest rates that affect the valuation of income-producing assets.